Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03666247 · ClinicalTrials.gov registry record · NA
Mobile Messaging Intervention to Present New HIV Prevention Options for Men Who Have Sex With Men (MSM)
A NA study, sponsored by Emory University.
- Completed
- Registry status
- NA
- Development phase
- 1,229
- Enrollment target
NCT03666247: Completed NA study, sponsored by Emory University.
NCT03666247 is a NA study that has completed, run by Emory University. The registered enrollment target is 1,229 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (12% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03666247, a NA study, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- NA
- Development phase
- 1,229 participants
- Enrollment target
Study Summary
The study will evaluate the use and effectiveness of mobile-messaging platforms as a public health strategy for improving sexual health outcome measures among men who have sex with men (MSM) by determining whether exposure to the message-delivery platform results in improvements in participants' self-reported sexual health and prevention behaviors, beliefs and attitudes. The study will enroll men into a randomized controlled trial. Participants randomized to the messaging intervention will have access to a smartphone-based messaging platform for three months while those assigned to the waitlist group will be offered access to the messaging platform after all follow up is complete. Participants will complete surveys at baseline, after the end of the 3 month intervention, and follow up surveys 6 and 9 months after the baseline survey.
Primary Outcome
HIV-negative men will be asked if they have received an HIV test (ever for the baseline measure and in the past 3 months for follow up surveys).
Interventions
- BEHAVIORAL Waitlist
- BEHAVIORAL HealthMindr Application
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,229 participants |
| Start Date | 2018-01-24 |
| Est. Completion | 2019-12-18 |
| Phase | NA |
What the finished NCT03666247 record still lists
NCT03666247 is an interventional study that assigns participants to a tested intervention. Its 1,229 participants enrollment target places it among the larger protocols in the corpus, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (12% lower).
The record links to 0 conditions, and to 2 interventions - of which Waitlist is the first listed.
NCT03666247 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03666247 about?
NCT03666247 is a clinical study titled "Mobile Messaging Intervention to Present New HIV Prevention Options for Men Who Have Sex With Men (MSM)". The study will evaluate the use and effectiveness of mobile-messaging platforms as a public health strategy for improving sexual health outcome measures among men who have sex with men (MSM) by determining whether exposure to the message-delivery platform results in improvements in participants' sel...
What is the current status of trial NCT03666247?
This trial is currently completed. It is a NA study. The enrollment target is 1,229 participants. The study started on 2018-01-24. Estimated completion is 2019-12-18.
What interventions are being tested in trial NCT03666247?
The interventions under investigation include: Waitlist (BEHAVIORAL), HealthMindr Application (BEHAVIORAL).
Who is sponsoring clinical trial NCT03666247?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03666247's enrollment target sits among peer trials
1,229 83rd of 2000 higher than 1,918 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05946044 · 1,230 participants · NA
The Osteoarthritis Prevention Study
- NCT06787937 · 1,230 participants · NA
Communicating About Nicotine Reduction in Cigarettes
- NCT05456841 · 1,232 participants · NA
Empathic Communication Skills (ECS) Training
- NCT06921785 · 1,220 participants · Phase 3
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI